News
Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.
Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.
Maciej Wieczorek on the strategies of developing innovative medicines at the 11th Multiciplinary conference on pharmaeutical science “Science for the Industry, Industry for science”
On 16 November this year, President of the Management Board of Celon Pharma S.A. will give a lecture discussing the discovery and implementation of innovations in the pharmaceutical sector on the example of drug candidates developed under Celon Pharma’s clinical programmes. He will also participate in an expert debate entitled: “Business for science”. We encourageRead more »
Celon Pharma on the development of cancer drugs at the ORTC-NCI-AACR SYMPOSIUM
Aleksandra Stańczak, PhD, Leader of the Oncology Research Group will present results for two inhibitors under Celon Pharma’s development at the 30th symposium organised by European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR), to be held on 13-16. November in Dublin. The followingRead more »
Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor
Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor
Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor
The Company’s anti-cancer drug – (CPL304110) – might be indicated for patients with lung, bladder and stomach tumours which have genetic aberrations of FGFR kinases. The objective of the trial will be to determine the drug’s safety profile (including MTD) and observation of early symptoms of drug activity in the trial subjects. The clinical trialRead more »
Celon Pharma at ESMO 2018
Representatives of the Oncology Research Group will take part in ESMO 2018, a congress organised by the European Society for Medical Oncology, which will be held on 19 October in Munich. In the course of the congress, they will present selected results of preclinical trials for the FGFR inhibitor at a poster session held onRead more »
The first stage of building Celon Pharma’s R&D Centre in Kazuń Nowy is on the home run and in line with the Company’s investment plan
Conclusion of the building shell stage was celebrated with symbolic topping out, which was carried out by representatives of Celon Pharma S.A. and Skanska, the General Contractor, on 15 October. The task commissioned by Celon Pharma includes general contracting of the building shell together with internal installation systems, roads and external area, as well asRead more »
Celon Pharma will present results of its research on esketamine and the PDE10A inhibitor at the 31st European College of Neuropsychopharmacology Congress in Barcelona
During the three days of the congress, more than 6,000 participants from all over the world: psychiatrists, psychologists and neurologists, will discuss the most important scientific reports in the field of diagnosis and treatment of brain diseases, from primary research to clinical development. Representatives of the Oncology Research Group will present three poster session topicsRead more »
Celon Pharma on Esketamine at the 3rd Central European Biomedical Congress (CEBC)
Representatives of the Celon Pharma Neuropsychiatry Research Group took part in the 3rd Central European Biomedical Congress (CEBC) which was held on 15-18 September this year. This is the largest scientific conference dedicated to preclinical research and biomedical sciences in our part of Europe. The theme of this year’s edition was, among others, neuropsychiatry. DuringRead more »